Stockreport

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX Inc. COmmon Stock  (PHGE) 
PDF BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b [Read more]